Andrx To Launch Lovastatin XL In 2002 With 150-Rep Sales Force
Executive Summary
Andrx plans to launch extended-release lovastatin in 2002 for hyperlipidemia with three years of exclusivity, President Elliot Hahn, PhD, announced March 28 at the Banc of America Securities Healthcare Conference in Las Vegas.
You may also be interested in...
Andrx lovastatin XL approved
Andrx plans to launch extended-release Altocor (lovastatin) in the third quarter with a 280-rep sales force. The product was approved June 26. "At steady state in humans, the bioavailability of lovastatin, following the administration of Altocor, was 190% compared to lovastatin immediate-release," labeling states. The NDA for the cholesterol-lowering agent was filed March 29, 2001 (1"The Pink Sheet" April 2, 2001, p. 15)...
Andrx lovastatin XL approved
Andrx plans to launch extended-release Altocor (lovastatin) in the third quarter with a 280-rep sales force. The product was approved June 26. "At steady state in humans, the bioavailability of lovastatin, following the administration of Altocor, was 190% compared to lovastatin immediate-release," labeling states. The NDA for the cholesterol-lowering agent was filed March 29, 2001 (1"The Pink Sheet" April 2, 2001, p. 15)...
Andrx lovastatin XL “approvable”
Andrx' extended-release lovastatin Altocor (formally Avicor) receives "approvable" letter for treatment of hyperlipidemia. The NDA was filed March 29 (1"The Pink Sheet" April 2, 2001, p. 15)...